JPRN-jRCT2031210589Active, not recruiting未知
A special drug use-results survey to evaluate the safety and efficacy of subcutaneous administration of Cosentyx in pediatric patients with psoriasis vulgaris, psoriatic arthritis, or pustular psoriasis
Toshiya Sugimoto0 sites35 target enrollmentStarted: January 31, 2022Last updated:
Trial Snapshot
- Phase
- 未知
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 35
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- ot applicable to < 18age old (—)
- Sex
- All
Inclusion Criteria
- •1.Patients who have obtained written consent from their legally acceptable representative to cooperate in this survey before the start of treatment with this drug
- •2.Patients aged less than 18 years at the start of treatment with this drug
- •3.Patients newly treated with this drug for any of the following diseases: Psoriasis vulgaris, psoriatic arthritis, pustular psoriasis
Exclusion Criteria
- •1.Prior treatment with this drug
- •2.Participation in an interventional study (e.g., a clinical trial) at the time of starting this drug.
Investigators
Similar Trials
Recruiting
Unknown
Special Drug Use-Results Survey (All-Case Surveillance) to Investigate Safety and Effectiveness in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Received Empaveli in the Post-Marketing Clinical Use in JapaParoxysmal nocturnal hemoglobinuriaJPRN-jRCT2031230275Shimmoto Naoki100
Recruiting
Not Applicable
Special Drug Use Results Survey for the use of Symtuza in pregnant womeJPRN-UMIN000037488Janssen Pharmaceutical K.K.3
Completed
Not Applicable
Special Drug Use-Results Survey for Long-term Use of XEPLION TRI Aqueous Suspension for IM Injection 175 mg, 263 mg, 350 mg, and 525 mg SyringeSchizophreniaJPRN-UMIN000042033Janssen Pharma990
Completed
Not Applicable
Specified Drug Use-Results Survey on "long-term use for Nouriast Tablet "s diseaseParkinson's diseaseJPRN-UMIN000030014Kyowa Hakko Kirin Co., Ltd.1,000
Not yet recruiting
Not Applicable
Evaluation Of Drug Usage In Cardiac PatientsCTRI/2021/01/030356il